MIRA
INFORM REPORT
|
Report Date : |
22.10.2008 |
IDENTIFICATION
DETAILS
|
Name : |
BIODOT, INC |
|
|
|
|
Registered Office : |
17781 Sky Park CircleIrvine, CA 92614 |
|
|
|
|
Country : |
United States |
|
|
|
|
Date of Incorporation : |
23.03.1994 |
|
|
|
|
Com. Reg. No.: |
C1884670 |
|
|
|
|
Legal Form : |
Corporation – Profit |
|
|
|
|
Line of Business : |
Suppliers of System Tools for the Research, Development and
Commercialization of Diagnostic Tests. |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Company
Name
BIODOT, INC
Contact Information
|
Address |
17781 Sky Park Circle Irvine, CA 92614 USA |
|
Telephone |
949-440-3685 |
|
Fax |
949-440-3694 |
|
Website |
www.biodot.com |
Registration Data
|
Date of Registration |
March 23, 1994 |
|
Registration number |
C1884670 |
|
Legal address |
17781 Sky Park Circle Irvine, CA 92614 USA |
|
Legal Form |
Corporation – Profit |
|
Share Capital |
- |
|
Other Registration Data |
- |
Shareholders
with Shares
|
Shareholder Names |
Share% |
|
Private |
100% |
Board/Executive
|
Name |
Thomas C. TISONE |
|
Position within the company |
President & CEO |
|
Name |
Barbara McINTOSH |
|
Position within the company |
Vice President |
Changes in
Registration Data
None recorded
Activities
(realistic and officials)
BioDot is one of the leading suppliers of system tools for the research,
development and commercialization of diagnostic tests. Its mission is to
enable, inspire and educate scientist to commercialize their ideas from
research and development to manufactured product.
Using its core competencies in low-volume, non-contact dispensing and
technology transfer services, BioDot has developed a range of equipment for the
research and development and manufacture of biosensor, biochips, immunoblots,
dry chemistry and lateral flow applications.
Staff
|
Number of staff employed |
30 |
Export/Import
(Countries, goods and total values for the period)
|
Imports From |
Europe, Far East |
|
Exports To |
Worldwide |
Facilities
|
Rented |
Laboratory and office |
|
Premises Size |
14,500 sq. feet |
Subsidiaries
and Participation
|
Parent Company |
- |
|
Subsidiaries |
BioDot, Ltd |
|
Affiliates |
- |
Branches
|
Address |
- |
Bankers
|
Bank |
Comerica Bank |
|
Address |
301 E Ocean Blvd # 102, Long Beach, CA 90802 |
|
Telephone |
(562) 590-2500 |
Suppliers,
Partners
|
Suppliers |
Not known |
|
Partners |
Not known |
Litigation,
Remarks on Payment
|
Litigation |
None Recorded |
|
Remarks on Payment |
No Complaints |
There is one UCC file listed with the Secretary of Ste of California:
|
UCC Filed Date: |
04/14/2005 |
|
Expiration Date: |
04/14/2010 |
|
Filing Number: |
057022918529 |
|
|
|
|
Secured Party: |
CALIFORNIA ECONOMIC DEVELOPMENT LENDING 1333 Broadway, Suite 604, Oakland, CA 94612 |
|
|
|
Financial
Information
|
Source |
Bank |
|
Figures are |
Estimate |
|
Currency |
USD |
|
Months |
Sales Figures |
Sales |
|
12 |
31/12/2007 |
3,000,000 |
Reporter Comments
|
Comments |
On a direct call, nobody was available to answer
our questions. We sent a fax but no answer was received. |
|
Local Reputation |
The company being investigated is believed by local reporters to be a Medium Trade Risk and to be
fair. According to our credit analysts, during the last 6 months, 82% of
trade experience indicates a regular payment. Payments of imports are currently made with an average of 20 days
beyond terms. |
|
MAX CREDIT |
USD 60,000= |
NEWS
|
Source |
Company News |
|
Article |
November 19, 2008 - November 22, 2008 |
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.29 |
|
UK Pound |
1 |
Rs.80.40 |
|
Euro |
1 |
Rs.63.35 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)